This decision would allow companies to decide for themselves to whom they wish to sell their vaccines.
“We have ensured an adequate supply of vaccines for all Americans. This is a direct result of the President taking aggressive steps, including through the Defense Production Act, to mobilize the full force of manufacturing and of vaccine production in the United States, “White House Covid-19 response coordinator Jeff Zients told reporters at a virtual press conference.
“Because of these actions and the success of US vaccine manufacturers, we are confident in our supply of our licensed vaccines. As a result, we are removing DPA priority ratings for AstraZeneca, Novavax and Sanofi.
While the manufacturers will continue to manufacture these three vaccines, this move will allow the US-based companies that supply these vaccine manufacturers to make their own decisions about which orders to fill first, ”Zients said.
The official said President Biden is committed to the United States being a vaccine arsenal. America’s work on vaccine supply is guided by a three-part approach, he added.
“First, after we have succeeded in ensuring an adequate supply of vaccines for Americans, we donate a surplus of vaccine to the United States and encourage other countries with a surplus of supply to do the same. Mexico and the President have announced a US commitment to share a total of 80 million doses by the end of June, ”he said.
“That’s five times the number of doses that another country has pledged to share and those 80 million doses represent 13% of the total vaccines produced by the United States by the end of this month. will continue to donate additional doses through the summer month as supplies become available, ”he added.
“But at the same time, we know it won’t be enough, so the second part of our approach is to work with the American vaccine makers to dramatically increase the vaccine supply to the rest of the world in a way that creates also jobs here at home, ”he said.
The third part of the approach will have the United States working with its partner countries, pharmaceutical companies and other manufacturers to facilitate the kind of global vaccine manufacturing and production capacity and capabilities that not only help the world to defeat this pandemic, but also prepare the world to respond to potential future threats, he said.
“Today we are setting our framework to share the first 25 million doses with the world. To be clear, our approach is to ensure that vaccines are distributed in a fair manner and in accordance with the latest scientific and public health data. “, did he declare. added.